CSPC Innovation Pharmaceutical Co., Ltd. (300765.SZ) announced that its subsidiary, Shijiazhuang Yiling Pharmaceutical's Jushi Biologics, has obtained topline analysis data from the Phase III clinical trial of its Secukinumab Injection.

The product, a biosimilar of Cosentyx®, is a fully human IgG1 monoclonal antibody developed by Jushi Biologics. Cosentyx® is approved in China for treating plaque psoriasis (ages 6+), psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, with established efficacy and safety profiles.

The pivotal study met its primary endpoints, demonstrating positive topline results. Statistical analysis confirmed the biosimilar's clinical equivalence to Cosentyx® with favorable safety outcomes, showing no new or unexpected safety signals. This positions the product to address long-term treatment safety needs for patients.

Detailed data will be presented at upcoming academic conferences and published in peer-reviewed journals.